Navigo Proteins GmbH

Navigo Proteins GmbH is a biotech startup based in Germany, founded in 2017, specializing in the discovery and development of novel scaffold proteins-based affinity ligands for biopharmaceutical manufacturing and biotherapeutics. The company's unique protein engineering expertise has resulted in the establishment of a versatile scaffold proteins platform, allowing for the rapid design, production, analysis, and selection of suitable affinity ligand proteins optimized for industrial downstream processing or as biopharmaceutical drugs. The company's Precision Capturing technology utilizes a protein A-like scaffold to enable an antibody-like capture step, even for non-Fc bearing molecules, offering competitive binding capacities, caustic stabilities, usage cycles, flow rates, and commercially available off-the-shelf leaching assays. This technology is applicable for purifying various biologics such as recombinant proteins, monoclonal antibodies, viruses, VLPs, and cells. Furthermore, Precision Targeting platform creates tailored ligands that bind to any desired biologic, facilitating applications in biopharmaceuticals, diagnostics, radiopharmaceuticals, protein-drug-conjugates, CAR-T ligands, theranostics, and treatment monitoring. Navigo Proteins has garnered global partnerships to convert their custom affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing, further establishing their presence in the biopharmaceutical and life sciences industry. With approximately 50 employees and a continuous growth trajectory, Navigo Proteins offers its expertise to interested pharma, biotech, and life sciences companies, positioning itself as a significant player in the biotechnology and pharmaceutical sectors.